Analyzing Phase 2 Data for PACAP Targeting Therapy Bocunebart in Migraine
Share
Subscribe
Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this Mind Moments episode, Jessica Ailani, MD, director of the MedStar Georgetown Headache Center, discusses emerging phase 2 data on bocunebart (Lundbeck), a PACAP-targeting monoclonal antibody being developed for migraine prevention. Presented at the 2026 American Headache Society Annual Meeting, findings from the PROCEED trial demonstrated efficacy in patients with episodic or chronic migraine who had previously failed 1 to 4 preventive therapies, including those considered treatment refractory.
The conversation explores the efficacy and safety findings from PROCEED, pooled analyses from chronic migraine populations, and a separate study evaluating coadministration of bocunebart with ubrogepant. Ailani also discusses the potential role of PACAP-targeting therapies within the evolving migraine treatment landscape, considerations for future combination strategies, and key questions investigators will need to address as the program moves toward phase 3 development.
Looking for more Headache & migraine discussion? Check out the NeurologyLive® Headache & migraine clinical focus page.
Episode Breakdown:
- 1:10 – PROCEED trial efficacy in patients with prior preventive failures
- 5:10 – Safety and tolerability findings for bocunebart
- 6:30 – Coadministration data with ubrogepant and clinical implications
- 8:30 – Neurology News Network
- 10:50 – Rationale for combining PACAP and CGRP-targeted therapies
- 13:40 – Key considerations for future phase 3 development
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:
Topline Phase 2 CELIA Results Show Diranersen Misses Primary End Point in Early Alzheimer Disease
FDA Grants Priority Review to Bayer’s Asundexian for Secondary Stroke Prevention
Dyne Submits BLA for Z-Rostudirsen in Exon 51 Skipping Duchenne Muscular Dystrophy
Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.